Steris price target raised to $280 from $265 at Citizens JMP

Citizens JMP raised the firm’s price target on Steris (STE) to $280 from $265 and keeps an Outperform rating on the shares. Steris ended fiscal 2025 with a strong quarter that included a marginal beat on the top line and 5% bottom-line upside, the analyst tells investors in a research note. The company has built an impressive track record of consistent execution and the portfolio remains largely non-elective in nature, and fiscal 2026 should be another solid year for the company and the stock, Citizens says.